Roland E Schmieder

List of Publications by Citations

338 papers	33,507 citations	71 h-index	180 g-index
369 ext. papers	40,079 ext. citations	6.1 avg, IF	6.68 L-index

#	Paper	IF	Citations
338	2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Journal of Hypertension*, **2007**, 25, 1105-87	1.9	3825
337	2018 ESC/ESH Guidelines for the management of arterial hypertension. *European Heart Journal*, **2018**, 39, 3021-3104	9.5	3698
336	2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Journal of Hypertension*, **2013**, 31, 1281-357	1.9	3363
335	Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. *Lancet, The*, **2010**, 376, 1903-9	40	1577
334	2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. *Journal of Hypertension*,	1.9	1262
333	Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. *Lancet, The*, **2008**, 372, 547-53	40	1179
332	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. *Journal of Hypertension*, **2009**, 27, 2121-58	1.9	1004
331	2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. *Journal of Hypertension*, **2007**, 25, 1751-62	1.9	871
330	2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. *Journal of Hypertension*, **2013**, 31, 1925-38	1.9	635
329	A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. *American Journal of Medicine*, **2003**, 115, 41-6	2.4	574
328	Renin-angiotensin system and cardiovascular risk. *Lancet, The*, **2007**, 369, 1208-19	40	507
327	2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. *Blood Pressure*, **2014**, 23, 3-16	1.7	474
326	Preeclampsia -- a state of sympathetic overactivity. *New England Journal of Medicine*, **1996**, 335, 1480-5	59.2	468
325	Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. *Circulation*, **2005**, 111, 1012-8	16.7	438
324	Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. *Lancet, The*, **2017**, 390, 2160-2170	40	406
323	Urinary sodium and potassium excretion and risk of cardiovascular events. *JAMA - Journal of the American Medical Association*, **2011**, 306, 2229-38	27.4	375
322	Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. *Lancet, The*, **2018**, 391, 2346-2355	40	358

321	Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. *Circulation*, **2012**, 126, 2976-82	16.7	343
320	Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. *Journal of the American College of Cardiology*, **2010**, 55, 2299-307	15.1	306
319	Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. *Lancet, The*, **2018**, 391, 2335-2345	40	301
318	2013 ESH/ESC Guidelines for the Management of Arterial Hypertension. *Blood Pressure*, **2013**, 22, 193-278	1.7	286
317	Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. *Hypertension*, **2012**, 60, 419-24	8.5	245
316	23Na magnetic resonance imaging-determined tissue sodium in healthy subjects and hypertensive patients. *Hypertension*, **2013**, 61, 635-40	8.5	243
315	Dietary salt intake. A determinant of cardiac involvement in essential hypertension. *Circulation*, **1988**, 78, 951-6	16.7	239
314	Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. *Circulation*, **1998**, 98, 211-6	16.7	211
313	Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. *Circulation*, **2013**, 128, 132-40	16.7	199
312	Changes in albuminuria predict mortality and morbidity in patients with vascular disease. *Journal of the American Society of Nephrology: JASN*, **2011**, 22, 1353-64	12.7	190
311	ESH position paper: renal denervation - an interventional therapy of resistant hypertension. *Journal of Hypertension*, **2012**, 30, 837-41	1.9	187
310	Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. *European Heart Journal*, **2014**, 35, 1752-9	9.5	186
309	Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. *Blood Pressure*, **2009**, 18, 308-47	1.7	186
308	Left ventricular hypertrophy and clinical outcomes in hypertensive patients. *American Journal of Hypertension*, **2008**, 21, 500-8	2.3	174
307	Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. *Lancet, The*, **2017**, 389, 2226-2237	40	171
306	Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. *Lancet, The*, **2020** , 395, 1444-1451	40	166
305	(23)Na magnetic resonance imaging of tissue sodium. *Hypertension*, **2012**, 59, 167-72	8.5	161
304	New approaches in the treatment of hypertension. *Circulation Research*, **2015**, 116, 1074-95	15.7	159

303	The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. *Journal of Hypertension*, **2008**, 26, 1487-96	1.9	159
302	Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. *Journal of Hypertension*, **2008**, 26, 403-11	1.9	151
301	Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). *Nephrology Dialysis Transplantation*, **1998**, 13, 564-9	4.3	140
300	First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension. *Hypertension*, **2015**, 65, 766-74	8.5	139
299	Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group Hypertension Arrhythmias and Thrombosis of the European Society of Hypertension. *Journal of Hypertension*, **2012**, 30, 239-52	1.9	138
298	Impaired endothelial function of the retinal vasculature in hypertensive patients. *Stroke*, **2004**, 35, 1289-93	8.7	126
297	Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial. *Lancet, The*, **2015**, 385, 1634-41	40	121
296	Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). *Circulation*, **2011**, 124, 1727-36	16.7	121
295	Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. *Journal of the American Society of Nephrology: JASN*, **2005**, 16, 3038-45	12.7	121
294	Impaired endothelial function in arterial hypertension and hypercholesterolemia: potential mechanisms and differences. *Journal of Hypertension*, **2000**, 18, 363-74	1.9	119
293	Salt and hypertension: is salt dietary reduction worth the effort?. *American Journal of Medicine*, **2012**, 125, 433-9	2.4	118
292	Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. *Circulation*, **2009**, 119, 417-25	16.7	116
291	Effect of telmisartan on renal outcomes: a randomized trial. *Annals of Internal Medicine*, **2009**, 151, 1-10, W1-2	8	116
290	Increased wall:lumen ratio of retinal arterioles in male patients with a history of a cerebrovascular event. *Hypertension*, **2007**, 50, 623-9	8.5	113
289	Skin Sodium Concentration Correlates with Left Ventricular Hypertrophy in CKD. *Journal of the American Society of Nephrology: JASN*, **2017**, 28, 1867-1876	12.7	112
288	Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. *American Heart Journal*, **2005**, 149, 473	4.9	110
287	Accuracy of Cuff-Measured Blood Pressure: Systematic Reviews and Meta-Analyses. *Journal of the American College of Cardiology*, **2017**, 70, 572-586	15.1	109
286	Rapid nongenomic effects of aldosterone on human forearm vasculature. *Hypertension*, **2003**, 42, 156-60	8.5	107

285	International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension. *Journal of the American College of Cardiology*, **2013**, 62, 2031-45	15.1	104
284	Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease. *International Journal of Cardiology*, **2013**, 168, 2214-20	3.2	101
283	Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. *Diabetes Care*, **2007**, 30, 1351-6	14.6	101
282	SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial. *Cardiovascular Diabetology*, **2018**, 17, 5	8.7	97
281	Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry. *European Heart Journal*, **2019**, 40, 3474-3482	9.5	95
280	Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension. *Journal of Hypertension*, **2012**, 30, 1047-55	1.9	95
279	Angiotensin II related to sodium excretion modulates left ventricular structure in human essential hypertension. *Circulation*, **1996**, 94, 1304-9	16.7	92
278	A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation. *Cardiovascular Diabetology*, **2017**, 16, 26	8.7	89
277	Beyond salt: lifestyle modifications and blood pressure. *European Heart Journal*, **2011**, 32, 3081-7	9.5	85
276	Reduced effect of percutaneous renal denervation on blood pressure in patients with isolated systolic hypertension. *Hypertension*, **2015**, 65, 193-9	8.5	84
275	Low-grade albuminuria and cardiovascular risk : what is the evidence?. *Clinical Research in Cardiology*, **2007**, 96, 247-57	6.1	84
274	Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus. *Circulation*, **2017**, 136, 1167-1169	16.7	78
273	Renal denervation preserves renal function in patients with chronic kidney disease and resistant hypertension. *Journal of Hypertension*, **2015**, 33, 1261-6	1.9	77
272	Effect of the angiotensin II type 2-receptor gene (+1675 G/A) on left ventricular structure in humans. *Journal of the American College of Cardiology*, **2001**, 37, 175-82	15.1	76
271	Renal denervation in moderate treatment-resistant hypertension. *Journal of the American College of Cardiology*, **2013**, 62, 1880-6	15.1	73
270	End organ damage in hypertension. *Deutsches Ärzteblatt International*, **2010**, 107, 866-73	2.5	73
269	Analysis of retinal arteriolar structure in never-treated patients with essential hypertension. *Journal of Hypertension*, **2008**, 26, 1427-34	1.9	71
268	Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. *International Journal of Clinical Practice*, **2007**, 61, 1461-8	2.9	70

267	Assessment of endothelial function of the renal vasculature in human subjects. *American Journal of Hypertension*, **2002**, 15, 3-9	2.3	69
266	Hypertension and the heart. *Journal of Human Hypertension*, **2000**, 14, 597-604	2.6	63
265	Glomerular hyperfiltration during sympathetic nervous system activation in early essential hypertension. *Journal of the American Society of Nephrology: JASN*, **1997**, 8, 893-900	12.7	63
264	Measurement of kidney perfusion by magnetic resonance imaging: comparison of MRI with arterial spin labeling to para-aminohippuric acid plasma clearance in male subjects with metabolic syndrome. *Nephrology Dialysis Transplantation*, **2010**, 25, 1126-33	4.3	62
263	Improvement of albuminuria after renal denervation. *International Journal of Cardiology*, **2014**, 173, 311-5	3.2	59
262	Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control Following Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial. *Circulation*, **2019**,	16.7	58
261	Cardiac performance after reduction of myocardial hypertrophy. *American Journal of Medicine*, **1989**, 87, 22-7	2.4	58
260	New developments in the pathogenesis of obesity-induced hypertension. *Journal of Hypertension*, **2015**, 33, 1499-508	1.9	56
259	Does obesity influence early target organ damage in hypertensive patients?. *Circulation*, **1993**, 87, 1482-8	16.7	56
258	Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial. *Journal of Hypertension*, **2014**, 32, 1888-97	1.9	55
257	Central pulse pressure is an independent determinant of vascular remodeling in the retinal circulation. *Hypertension*, **2013**, 61, 1340-5	8.5	55
256	Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. *European Heart Journal*, **2018**, 39, 3105-3114	9.5	54
255	Wall-to-lumen ratio of retinal arterioles and arteriole-to-venule ratio of retinal vessels in patients with cerebrovascular damage **2009**, 50, 4351-9		54
254	Updated ESH position paper on interventional therapy of resistant hypertension. *EuroIntervention*, **2013**, 9 Suppl R, R58-66	3.1	54
253	New software analyses increase the reliability of measurements of retinal arterioles morphology by scanning laser Doppler flowmetry in humans. *Journal of Hypertension*, **2011**, 29, 777-82	1.9	53
252	Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes. *Cardiovascular Diabetology*, **2014**, 13, 19	8.7	51
251	Wall-to-lumen ratio of retinal arterioles as a tool to assess vascular changes. *Hypertension*, **2009**, 54, 384-7	8.5	50
250	Accelerated decline in renal perfusion with aging in essential hypertension. *Hypertension*, **1994**, 23, 351-7	8.5	50

249	Left ventricular hypertrophy and its regression: pathophysiology and therapeutic approach: focus on treatment by antihypertensive agents. *American Journal of Hypertension*, **1998**, 11, 1394-404	2.3	48
248	Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. *Lancet, The*, **2021**, 397, 2476-2486	40	47
247	How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial. *Cardiovascular Diabetology*, **2019**, 18, 44	8.7	46
246	Remodeling of retinal small arteries in hypertension. *American Journal of Hypertension*, **2011**, 24, 1267-73	2.3	45
245	Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. *Journal of Hypertension*, **2009**, 27, 673-9	1.9	45
244	Adherence to Antihypertensive Medication in Treatment-Resistant Hypertension Undergoing Renal Denervation. *Journal of the American Heart Association*, **2016**, 5,	6	43
243	Rationale and design of a large registry on renal denervation: the Global SYMPLICITY registry. *EuroIntervention*, **2013**, 9, 484-92	3.1	42
242	Renal Denervation in High-Risk Patients With Hypertension. *Journal of the American College of Cardiology*, **2020**, 75, 2879-2888	15.1	41
241	Vascular and renal hemodynamic changes after renal denervation. *Clinical Journal of the American Society of Nephrology: CJASN*, **2013**, 8, 1195-201	6.9	41
240	A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs. *American Heart Journal*, **2018**, 195, 115-129	4.9	39
239	The role of nitric oxide in the regulation of glomerular haemodynamics in humans. *Nephrology Dialysis Transplantation*, **2004**, 19, 1392-7	4.3	39
238	Analysis of NO-synthase expression and clinical risk factors in human diabetic nephropathy. *Nephrology Dialysis Transplantation*, **2008**, 23, 1346-54	4.3	38
237	What the interventionalist should know about renal denervation in hypertensive patients: a position paper by the ESH WG on the interventional treatment of hypertension. *EuroIntervention*, **2014**, 9, 1027-35	3.1	38
236	Salt. A perpetrator of hypertensive target organ disease?. *Archives of Internal Medicine*, **1997**, 157, 2449-52		38
235	Renal Denervation Update From the International Sympathetic Nervous System Summit: JACC State-of-the-Art Review. *Journal of the American College of Cardiology*, **2019**, 73, 3006-3017	15.1	37
234	Obesity as a determinant for response to antihypertensive treatment. *BMJ: British Medical Journal*, **1993**, 307, 537-40		37
233	Renal Denervation for Treating Hypertension: Current Scientific and Clinical Evidence. *JACC: Cardiovascular Interventions*, **2019**, 12, 1095-1105	5	36
232	Renal resistive index in addition to low-grade albuminuria complements screening for target organ damage in therapy-resistant hypertension. *Journal of Hypertension*, **2010**, 28, 608-14	1.9	36

231	Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension. *Kidney International*, **2002**, 61, 1462-8	9.9	36
230	Effects of renal sympathetic denervation on urinary sodium excretion in patients with resistant hypertension. *Clinical Research in Cardiology*, **2015**, 104, 672-8	6.1	35
229	Improvement of hypertension management by structured physician education and feedback system: cluster randomized trial. *European Journal of Cardiovascular Prevention and Rehabilitation*, **2010**, 17, 271-9		35
228	Wall-to-lumen ratio of retinal arterioles is related with urinary albumin excretion and altered vascular reactivity to infusion of the nitric oxide synthase inhibitor N-monomethyl-L-arginine. *Journal of Hypertension*, **2009**, 27, 2201-8	1.9	35
227	Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET and TRANSCEND studies. *Diabetologia*, **2014**, 57, 2019-29	10.3	34
226	Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial. *Journal of Hypertension*, **2009**, 27, 1493-501	1.9	34
225	Physician attitudes to blood pressure control: findings from the Supporting Hypertension Awareness and Research Europe-wide survey. *Journal of Hypertension*, **2011**, 29, 1633-40	1.9	32
224	Increased response of renal perfusion to the antioxidant vitamin C in type 2 diabetes. *Nephrology Dialysis Transplantation*, **2004**, 19, 2513-8	4.3	32
223	Central pulse pressure predicts BP reduction after renal denervation in patients with treatment-resistant hypertension. *EuroIntervention*, **2015**, 11, 110-6	3.1	32
222	Central Iliac Arteriovenous Anastomosis for Uncontrolled Hypertension: One-Year Results From the ROX CONTROL HTN Trial. *Hypertension*, **2017**, 70, 1099-1105	8.5	31
221	Wilder☹ principle: pre-treatment value determines post-treatment response. *European Heart Journal*, **2015**, 36, 576-9	9.5	31
220	Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: a review of available trial evidence. *Journal of Hypertension*, **2014**, 32, 1741-50	1.9	31
219	Disproportional decrease in office blood pressure compared with 24-hour ambulatory blood pressure with antihypertensive treatment: dependency on pretreatment blood pressure levels. *Hypertension*, **2014**, 64, 1067-72	8.5	31
218	Tonic postganglionic sympathetic inhibition induced by afferent renal nerves?. *Hypertension*, **2012**, 59, 467-76	8.5	31
217	Why in 2016 are patients with hypertension not 100% controlled? A call to action. *Journal of Hypertension*, **2016**, 34, 1480-8	1.9	31
216	Alcohol-Mediated Renal Denervation Using the Peregrine System Infusion Catheter for Treatment of Hypertension. *JACC: Cardiovascular Interventions*, **2020**, 13, 471-484	5	30
215	Renal denervation in a hypertensive patient with end-stage renal disease and small arteries: a direction for future research. *Journal of Clinical Hypertension*, **2012**, 14, 799-801	2.3	30
214	Renal vascular endothelial function in hypertensive patients with type 2 diabetes mellitus. *American Journal of Kidney Diseases*, **2009**, 53, 281-9	7.4	30

213	Retinal capillary rarefaction in patients with untreated mild-moderate hypertension. *BMC Cardiovascular Disorders*, **2017**, 17, 300	2.3	28
212	Direct comparison of the effects of valsartan and amlodipine on renal hemodynamics in human essential hypertension. *American Journal of Hypertension*, **2003**, 16, 1030-5	2.3	28
211	Is l-arginine infusion an adequate tool to assess endothelium-dependent vasodilation of the human renal vasculature?. *Clinical Science*, **2000**, 99, 293-302	6.5	28
210	Non-invasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients: A consensus paper from the European Association of Cardiovascular Imaging (EACVI), the European Society of Cardiology Council on Hypertension, and the European Society of Hypertension (ESH). *European Heart Journal Cardiovascular Imaging*, **2017**, 18, 945-960	4.1	27
209	Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. *American Journal of Nephrology*, **2014**, 40, 572-81	4.6	27
208	Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia. *Atherosclerosis*, **2008**, 196, 704-11	3.1	27
207	Impact of dietary sodium intake on left ventricular diastolic filling in early essential hypertension. *European Heart Journal*, **1998**, 19, 951-8	9.5	27
206	Phase II randomized sham-controlled study of renal denervation for individuals with uncontrolled hypertension - WAVE IV. *Journal of Hypertension*, **2018**, 36, 680-689	1.9	24
205	Effects of manidipine vs. amlodipine on intrarenal haemodynamics in patients with arterial hypertension. *British Journal of Clinical Pharmacology*, **2013**, 75, 129-35	3.8	24
204	Blood pressure control in patients with comorbidities. *Journal of Clinical Hypertension*, **2008**, 10, 624-31	2.3	24
203	European Society of Hypertension position paper on renal denervation 2018. *Journal of Hypertension*, **2018**, 36, 2042-2048	1.9	24
202	Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk. *European Heart Journal*, **2019**, 40, 2032-2043	9.5	23
201	Externally Delivered Focused Ultrasound for Renal Denervation. *JACC: Cardiovascular Interventions*, **2016**, 9, 1292-1299	5	22
200	Reduction in basal nitric oxide activity causes albuminuria. *Diabetes*, **2011**, 60, 572-6	0.9	22
199	Impaired basal NO activity in patients with glomerular disease and the influence of oxidative stress. *Kidney International*, **2006**, 70, 1177-81	9.9	22
198	Impaired sodium excretion during mental stress in mild essential hypertension. *Hypertension*, **2001**, 37, 923-7	8.5	22
197	Angiotensin II stimulates left ventricular hypertrophy in hypertensive patients independently of blood pressure. *American Journal of Hypertension*, **1999**, 12, 418-422	2.3	22
196	Stress response pattern in obesity and systemic hypertension. *American Journal of Cardiology*, **1992**, 70, 1035-9	3	22

195	Renal denervation--implications for chronic kidney disease. *Nature Reviews Nephrology*, **2014**, 10, 305-13	14.9	21
194	Local application of tropicamide 0.5% reduces retinal capillary blood flow. *Blood Pressure*, **2013**, 22, 371-6	1.7	21
193	Basal nitric oxide synthase activity is a major determinant of glomerular haemodynamics in humans. *Journal of Hypertension*, **2008**, 26, 110-6	1.9	21
192	Medication adherence in hypertension. *Journal of Hypertension*, **2020**, 38, 579-587	1.9	21
191	Changes in Plasma Renin Activity After Renal Artery Sympathetic Denervation. *Journal of the American College of Cardiology*, **2021**, 77, 2909-2919	15.1	21
190	European Society of Hypertension position paper on renal denervation 2021. *Journal of Hypertension*, **2021**, 39, 1733-1741	1.9	21
189	Impaired increase of retinal capillary blood flow to flicker light exposure in arterial hypertension. *Hypertension*, **2012**, 60, 871-6	8.5	20
188	MASked-unconTrolled hypERtension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled trial protocol. *BMJ Open*, **2018**, 8, e021038	2	20
187	Relative and Combined Prognostic Importance of On-Treatment Mean and Visit-to-Visit Blood Pressure Variability in ONTARGET and TRANSCEND Patients. *Hypertension*, **2017**, 70, 938-948	8.5	19
186	12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation. *JACC: Cardiovascular Interventions*, **2020**, 13, 2922-2933	5	19
185	Plasma soluble adhesion molecules and endothelium-dependent vasodilation in early human atherosclerosis. *Clinical Science*, **2000**, 98, 521-529	6.5	19
184	Effect of Arteriovenous Anastomosis on Blood Pressure Reduction in Patients With Isolated Systolic Hypertension Compared With Combined Hypertension. *Journal of the American Heart Association*, **2016**, 5,	6	19
183	Low dose-eplerenone treatment decreases aortic stiffness in patients with resistant hypertension. *Journal of Clinical Hypertension*, **2017**, 19, 669-676	2.3	18
182	Renal protection by low dose irbesartan in diabetic nephropathy is paralleled by a reduction of inflammation, not of endoplasmic reticulum stress. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2014**, 1842, 558-65	6.9	18
181	Influence of blood flow on arteriolar wall-to-lumen ratio in the human retinal circulation in vivo. *Microvascular Research*, **2012**, 83, 111-7	3.7	18
180	Impact of NO-synthase inhibition on renal hemodynamics in normotensive and hypertensive subjects. *Journal of Hypertension*, **2002**, 20, 525-30	1.9	18
179	Confounding Factors in Renal Denervation Trials: Revisiting Old and Identifying New Challenges in Trial Design of Device Therapies for Hypertension. *Hypertension*, **2020**, 76, 1410-1417	8.5	18
178	Effects of linagliptin on renal endothelial function in patients with type 2 diabetes: a randomised clinical trial. *Diabetologia*, **2016**, 59, 2579-2587	10.3	18

177	Cocoa Flavanol Cardiovascular Effects Beyond Blood Pressure Reduction. *Journal of Clinical Hypertension*, **2016**, 18, 352-8	2.3	18
176	Blood Pressure Pattern and Target Organ Damage in Patients With Chronic Kidney Disease. *Hypertension*, **2018**, 72, 929-936	8.5	18
175	Patient preference for therapies in hypertension: a cross-sectional survey of German patients. *Clinical Research in Cardiology*, **2019**, 108, 1331-1342	6.1	17
174	Improvement in Retinal Capillary Rarefaction After Valsartan Treatment in Hypertensive Patients. *Journal of Clinical Hypertension*, **2016**, 18, 1112-1118	2.3	17
173	A guide for easy- and difficult-to-treat hypertension. *International Journal of Cardiology*, **2014**, 172, 17-22	3.2	17
172	Interpreting treatment-induced blood pressure reductions measured by ambulatory blood pressure monitoring. *Journal of Human Hypertension*, **2013**, 27, 715-20	2.6	17
171	Review of direct renin inhibition by aliskiren. *JRAAS - Journal of the Renin-Angiotensin-Aldosterone System*, **2013**, 14, 193-6	3	17
170	Renal denervation reduces office and ambulatory heart rate in patients with uncontrolled hypertension: 12-month outcomes from the global SYMPLICITY registry. *Journal of Hypertension*, **2016**, 34, 2480-2486	1.9	17
169	Renal denervation in hypertensive patients not on blood pressure lowering drugs. *Clinical Research in Cardiology*, **2016**, 105, 755-62	6.1	17
168	Antihypertensive therapy. To stop or not to stop?. *JAMA - Journal of the American Medical Association*, **1991**, 265, 1566-71	27.4	17
167	Clinical impact of patient adherence to a fixed-dose combination of olmesartan, amlodipine and hydrochlorothiazide. *Clinical Drug Investigation*, **2014**, 34, 403-11	3.2	16
166	Retinal Capillary Rarefaction in Patients with Type 2 Diabetes Mellitus. *PLoS ONE*, **2016**, 11, e0162608	3.7	16
165	Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials. *European Heart Journal*, **2020**, 41, 231-238	9.5	16
164	Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design. *Clinical Research in Cardiology*, **2020**, 109, 289-302	6.1	15
163	Influence of Age on Upper Arm Cuff Blood Pressure Measurement. *Hypertension*, **2020**, 75, 844-850	8.5	15
162	Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry. *BMC Cardiovascular Disorders*, **2016**, 16, 56	2.3	15
161	Hypertension: How should data from SYMPLICITY HTN-3 be interpreted?. *Nature Reviews Cardiology*, **2014**, 11, 375-6	14.8	15
160	Clinical situations associated with difficult-to-control hypertension. *Journal of Hypertension*, **2013**, 31 Suppl 1, S3-8	1.9	15

159	L-arginine-induced vasodilation of the renal vasculature is not altered in hypertensive patients with type 2 diabetes. *Diabetes Care*, **2003**, 26, 1836-40	14.6	15
158	25-hydroxyvitamin D insufficiency is associated with impaired renal endothelial function and both are improved with rosuvastatin treatment. *Clinical Research in Cardiology*, **2013**, 102, 299-304	6.1	14
157	Effects of folic acid on renal endothelial function in patients with diabetic nephropathy: results from a randomized trial. *Clinical Science*, **2014**, 127, 499-505	6.5	14
156	Rosuvastatin improves pulse wave reflection by restoring endothelial function. *Microvascular Research*, **2012**, 84, 60-4	3.7	14
155	Efficacy and safety of olmesartan medoxomil plus amlodipine in age, gender and hypertension severity defined subgroups of hypertensive patients. *Journal of Human Hypertension*, **2011**, 25, 354-63	2.6	14
154	Salt intake, blood pressure, and cardiovascular structure. *Cardiovascular Drugs and Therapy*, **1994**, 8, 425-32	3.4	14
153	Renal protection with angiotensin receptor blockers: where do we stand. *Journal of Nephrology*, **2011**, 24, 569-80	4.8	14
152	Reproducibility of Kidney Perfusion Measurements With Arterial Spin Labeling at 1.5 Tesla MRI Combined With Semiautomatic Segmentation for Differential Cortical and Medullary Assessment. *Medicine (United States)*, **2016**, 95, e3083	1.8	14
151	Renal impairment and worsening of renal function in acute heart failure: can new therapies help? The potential role of serelaxin. *Clinical Research in Cardiology*, **2015**, 104, 621-31	6.1	13
150	Retinal capillary and arteriolar changes in patients with chronic kidney disease. *Microvascular Research*, **2018**, 118, 121-127	3.7	13
149	Individualised treatment targets in patients with type-2 diabetes and hypertension. *Cardiovascular Diabetology*, **2018**, 17, 18	8.7	13
148	Guía de práctica clínica de la ESH/ESC para el manejo de la hipertensión arterial (2013). *Revista Espanola De Cardiologia*, **2013**, 66, 880.e1-880.e64	1.5	13
147	Validation of a therapeutic scheme for the treatment of resistant hypertension. *Journal of the American Society of Hypertension*, **2011**, 5, 498-504		13
146	Basal nitric oxide activity is an independent determinant of arteriolar structure in the human retinal circulation. *Journal of Hypertension*, **2011**, 29, 123-9	1.9	13
145	The role of statins in the treatment of the metabolic syndrome. *Current Hypertension Reports*, **2009**, 11, 143-9	4.7	13
144	High sodium intake modulates left ventricular mass in patients with G expression of +1675 G/A angiotensin II receptor type 2 gene. *Journal of Hypertension*, **2007**, 25, 1627-32	1.9	13
143	Relation of the first hypertension-associated event with medication, compliance and persistence in naïve hypertensive patients after initiating monotherapy. *International Journal of Clinical Pharmacology and Therapeutics*, **2010**, 48, 173-83	2	13
142	Early vascular parameters in the micro- and macrocirculation in type 2 diabetes. *Cardiovascular Diabetology*, **2018**, 17, 128	8.7	13

141	Changes in 24-Hour Patterns of Blood Pressure in Hypertension Following Renal Denervation Therapy. *Hypertension*, **2019**, HYPERTENSIONAHA11913081	8.5	12
140	Effectiveness and tolerability of a fixed-dose combination of olmesartan and amlodipine in clinical practice. *Vascular Health and Risk Management*, **2010**, 6, 803-11	4.4	12
139	Tissue sodium content in patients with type 2 diabetes mellitus. *Journal of Diabetes and Its Complications*, **2019**, 33, 485-489	3.2	11
138	Renal denervation improves 24-hour central and peripheral blood pressures, arterial stiffness, and peripheral resistance. *Journal of Clinical Hypertension*, **2018**, 20, 366-372	2.3	11
137	Impact of renal denervation on tissue Na content in treatment-resistant hypertension. *Clinical Research in Cardiology*, **2018**, 107, 42-48	6.1	11
136	Predictors of atherosclerotic events in patients on haemodialysis: post hoc analyses from the AURORA study. *Nephrology Dialysis Transplantation*, **2018**, 33, 102-112	4.3	11
135	Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk: a Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease subanalysis. *Journal of Hypertension*, **2014**, 32, 1334-41	1.9	11
134	First experience in analysing pulsatile retinal capillary flow and arteriolar structural parameters measured noninvasively in hypertensive patients. *Journal of Hypertension*, **2014**, 32, 2246-52; discussion 2252	1.9	11
133	Poor glycemic control is related to increased nitric oxide activity within the renal circulation of patients with type 2 diabetes. *Diabetes Care*, **2013**, 36, 4071-5	14.6	11
132	Reversibility of the effects of aliskiren in the renal versus systemic circulation. *Clinical Journal of the American Society of Nephrology: CJASN*, **2012**, 7, 258-64	6.9	11
131	Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial.. *Lancet, The*, **2022**, 399, 1401-1410	40	11
130	Circadian rhythm and day to day variability of serum potassium concentration: a pilot study. *Journal of Nephrology*, **2015**, 28, 165-72	4.8	10
129	Barriers to cardiovascular risk prevention and management in Germany--an analysis of the EURIKA study. *Vascular Health and Risk Management*, **2012**, 8, 177-86	4.4	10
128	Effects of angiotensin II type 1-receptor blockade on retinal endothelial function. *Journal of Hypertension*, **2008**, 26, 516-22	1.9	10
127	Renal hemodynamic response to stress is influenced by ACE-inhibitors. *Clinical Nephrology*, **1994**, 42, 381-8	2.1	10
126	Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. *Nephrology Dialysis Transplantation*, **2021**,	4.3	10
125	Early Signs of End-Organ Damage in Retinal Arterioles in Patients with Type 2 Diabetes Compared to Hypertensive Patients. *Microcirculation*, **2016**, 23, 447-55	2.9	10
124	Effects of the nitric oxide synthase inhibitor ronopterin (VAS203) on renal function in healthy volunteers. *British Journal of Clinical Pharmacology*, **2019**, 85, 900-907	3.8	9

123	Facing the Challenge of Lowering Blood Pressure and Cholesterol in the Same Patient: Report of a Symposium at the European Society of Hypertension. *Cardiology and Therapy*, **2020**, 9, 19-34	2.8	9
122	Effect of aliskiren on vascular remodelling in small retinal circulation. *Journal of Hypertension*, **2015**, 33, 2491-9	1.9	9
121	Urinary albumin excretion from spot urine samples predict all-cause and stroke mortality in Africans. *American Journal of Hypertension*, **2014**, 27, 811-8	2.3	9
120	Is l-arginine infusion an adequate tool to assess endothelium-dependent vasodilation of the human renal vasculature?. *Clinical Science*, **2000**, 99, 293	6.5	9
119	Effects of angiotensin converting enzyme inhibitor on renal haemodynamics during mental stress. *Journal of Hypertension*, **1996**, 14, 1201-7	1.9	9
118	Mid-Term Vascular Safety of Renal Denervation Assessed by Follow-up MR Imaging. *CardioVascular and Interventional Radiology*, **2016**, 39, 426-32	2.7	8
117	Changes in Stroke Volume After Renal Denervation: Insight From Cardiac Magnetic Resonance Imaging. *Hypertension*, **2020**, 75, 707-713	8.5	8
116	Telmisartan in incipient and overt diabetic renal disease. *Journal of Nephrology*, **2011**, 24, 263-73	4.8	8
115	Differences in patient and physician perspectives on pharmaceutical therapy and renal denervation for the management of hypertension. *Journal of Hypertension*, **2021**, 39, 162-168	1.9	8
114	Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes. *European Heart Journal - Cardiovascular Pharmacotherapy*, **2020**, 6, 364-371	6.4	8
113	Improved cardiovascular risk prediction in patients with end-stage renal disease on hemodialysis using machine learning modeling and circulating microribonucleic acids. *Theranostics*, **2020**, 10, 8665-8676	12.1	8
112	Aortic stiffness is not only associated with structural but also functional parameters of retinal microcirculation. *Microvascular Research*, **2020**, 129, 103974	3.7	7
111	Retinal vascular resistance in arterial hypertension. *Blood Pressure*, **2018**, 27, 82-87	1.7	7
110	Attenuation of Splanchnic Autotransfusion Following Noninvasive Ultrasound Renal Denervation: A Novel Marker of Procedural Success. *Journal of the American Heart Association*, **2018**, 7,	6	7
109	Does renal artery supply indicate treatment success of renal denervation?. *CardioVascular and Interventional Radiology*, **2013**, 36, 987-91	2.7	7
108	Guía de práctica clínica de la ESH/ESC para el manejo de la hipertensión arterial (2013). *Hipertension Y Riesgo Vascular*, **2013**, 30, 4-91	0.5	7
107	Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: prospective case series. *Hypertension*, **2013**, 61, e17	8.5	7
106	Patients With Newly Diagnosed Hypertension Treated With the Renin Angiotensin Receptor Blocker Azilsartan Medoxomil vs Angiotensin-Converting Enzyme Inhibitors: The Prospective EARLY Registry. *Journal of Clinical Hypertension*, **2015**, 17, 947-53	2.3	7

105	Achievement of individualized treatment targets in patients with comorbid type-2 diabetes and hypertension: 6 months results of the DIALOGUE registry. *BMC Endocrine Disorders*, **2015**, 15, 23	3.3	7
104	Optimizing blood pressure control in hypertension: the need to use ABPM. *Blood Pressure*, **2013**, 22, 65-72	1.7	7
103	Cerebral microangiopathy in treatment-resistant hypertension. *Journal of Clinical Hypertension*, **2011**, 13, 582-7	2.3	7
102	Renal denervation: where do we stand and what is the relevance to the nephrologist?. *Nephrology Dialysis Transplantation*, **2020**,	4.3	7
101	The effect of renal denervation in moderate treatment-resistant hypertension with confirmed medication adherence. *Journal of Hypertension*, **2016**, 34, 2475-2479	1.9	7
100	Effects of renal denervation on blood pressure in hypertensive patients with end-stage renal disease: a single centre experience. *Clinical and Experimental Nephrology*, **2019**, 23, 749-755	2.5	7
99	Effect of renal denervation in attenuating the stress of morning surge in blood pressure: post-hoc analysis from the SPYRAL HTN-ON MED trial. *Clinical Research in Cardiology*, **2021**, 110, 725-731	6.1	7
98	Diuretic therapy and the risk for renal cell carcinoma. *Journal of Nephrology*, **2000**, 13, 343-6	4.8	7
97	Rosuvastatin does not affect intrarenal hemodynamics in patients with hypercholesterolemia. *Journal of Nephrology*, **2009**, 22, 675-81	4.8	7
96	Scientific Data and Transparency of Conflict of Interest Are Important, Not Biased Editorial Without Facts. *JACC: Cardiovascular Interventions*, **2016**, 9, 2263	5	6
95	EARLY Treatment with azilsartan compared to ACE-inhibitors in anti-hypertensive therapy--rationale and design of the EARLY hypertension registry. *BMC Cardiovascular Disorders*, **2013**, 13, 46	2.3	6
94	Olmesartan improves pulse wave velocity and lowers central systolic blood pressure and ambulatory blood pressure in patients with metabolic syndrome. *Journal of Clinical Hypertension*, **2015**, 17, 98-104	2.3	6
93	Angiotensin blockade to reduce microvascular damage in diabetes mellitus. *Deutsches Ärzteblatt International*, **2009**, 106, 556-62	2.5	6
92	The potential role of prorenin in diabetic nephropathy. *Journal of Hypertension*, **2007**, 25, 1323-6	1.9	6
91	Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure. *Cardiovascular Diabetology*, **2021**, 20, 219	8.7	6
90	Renal denervation in patients with versus without chronic kidney disease: results from the global SYMPLICITY Registry with follow-up data of 3 years. *Nephrology Dialysis Transplantation*, **2021**,	4.3	6
89	Non-invasive Renal Denervation: Update on External Ultrasound Approaches. *Current Hypertension Reports*, **2016**, 18, 48	4.7	6
88	Renal Denervation for Resistant Hypertension: Past, Present, and Future. *Current Hypertension Reports*, **2015**, 17, 65	4.7	5

87	Invasive treatment of resistant hypertension: present and future. *Current Hypertension Reports*, **2014**, 16, 488	4.7	5
86	Prevention of electrocardiographic left ventricular remodeling by the angiotensin receptor blocker olmesartan in patients with type 2 diabetes. *Journal of Hypertension*, **2014**, 32, 2267-76; discussion 2276	1.9	5
85	Oxidized LDL, statin use, morbidity, and mortality in patients receiving maintenance hemodialysis. *Free Radical Research*, **2017**, 51, 14-23	4	5
84	Change in augmentation index during NOS inhibition, an index of basal NO production, is an independent determinant of large-artery function. *Kidney and Blood Pressure Research*, **2010**, 33, 343-51	3.1	5
83	Pharmacokinetics of Valsartan in Hypertensive Patients on Long-Term Haemodialysis. *Clinical Drug Investigation*, **2001**, 21, 59-66	3.2	5
82	Catheter-based Renal Sympathetic Denervation - Long-term Symplicity Renal Denervation Clinical Evidence, New Data and Future Perspectives. *Interventional Cardiology Review*, **2013**, 8, 118-123	4.2	5
81	Ruling out secondary causes of hypertension. *EuroIntervention*, **2013**, 9 Suppl R, R21-8	3.1	5
80	Diagnosis and treatment of arterial hypertension 2021. *Kidney International*, **2021**,	9.9	5
79	The Effect of Resting Heart Rate on the New Onset of Microalbuminuria in Patients With Type 2 Diabetes: A Subanalysis of the ROADMAP Study. *Medicine (United States)*, **2016**, 95, e3122	1.8	5
78	Central arteriovenous anastomosis to treat resistant hypertension. *Current Opinion in Nephrology and Hypertension*, **2018**, 27, 8-15	3.5	5
77	Effect of Heart Rate on the Outcome of Renal Denervation in Patients With Uncontrolled Hypertension. *Journal of the American College of Cardiology*, **2021**, 78, 1028-1038	15.1	5
76	Retinal microperfusion after renal denervation in treatment-resistant hypertensive patients. *Clinical Research in Cardiology*, **2015**, 104, 782-9	6.1	4
75	3D-Visualization of Neurovascular Compression at the Ventrolateral Medulla in Patients with Arterial Hypertension. *Clinical Neuroradiology*, **2021**, 31, 335-345	2.7	4
74	Percutaneous Creation of a Central Iliac Arteriovenous Anastomosis for the Treatment of Arterial Hypertension. *Current Hypertension Reports*, **2018**, 20, 18	4.7	4
73	The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry. *Trials*, **2015**, 16, 581	2.8	4
72	Renal and systemic hemodynamics in black and white hypertensive patients. *American Journal of Hypertension*, **1997**, 10, 971-8	2.3	4
71	P-204: Aliskiren, a novel orally effective renin inhibitor, provides antihypertensive efficacy and placebo-like tolerability similar to an at1-receptor blocker in hypertensive patients. *American Journal of Hypertension*, **2004**, 17, S108	2.3	4
70	Risks versus benefits of withdrawing antihypertensive therapy. *Drug Safety*, **1992**, 7, 395-403	5.1	4

69	Hypertensive heart disease--significance of left ventricular hypertrophy. *Journal of Cardiovascular Pharmacology*, **1992**, 20 Suppl 6, S50-5	3.1	4
68	Visit-to-visit blood pressure variability and renal outcomes: results from ONTARGET and TRANSCEND trials. *Journal of Hypertension*, **2020**, 38, 2050-2058	1.9	4
67	Left Ventricular Structure in Patients With Mild-to-Moderate CKD-a Magnetic Resonance Imaging Study. *Kidney International Reports*, **2019**, 4, 267-274	4.1	4
66	Improved blood pressure control via a novel chronic disease management model of care in sub-Saharan Africa: Real-world program implementation results. *Journal of Clinical Hypertension*, **2021**, 23, 785-792	2.3	4
65	Secretory Capacity of Pancreatic Beta-Cells Is Enhanced 6 Months After Renal Denervation in Hypertensive Patients. *Journal of the American College of Cardiology*, **2018**, 72, 3372-3374	15.1	4
64	Catheter-based alcohol-mediated renal denervation for the treatment of uncontrolled hypertension: design of two sham-controlled, randomized, blinded trials in the absence (TARGET BP OFF-MED) and presence (TARGET BP I) of antihypertensive medications. *American Heart Journal*, **2021**, 239, 90-99	4.9	4
63	Retinal neurodegeneration in patients with end-stage renal disease assessed by spectral-domain optical coherence tomography. *Scientific Reports*, **2020**, 10, 5255	4.9	3
62	Diagnosis and treatment of resistant hypertension. *Blood Pressure*, **2014**, 23, 193-9	1.7	3
61	Haemoglobin and vascular function in the human retinal vascular bed. *Journal of Hypertension*, **2013**, 31, 775-81	1.9	3
60	Comment on ESH position paper. *Journal of Hypertension*, **2012**, 30, 2443	1.9	3
59	Significance of initial blood pressure and comorbidity for the efficacy of a fixed combination of an angiotensin receptor blocker and hydrochlorothiazide in clinical practice. *Vascular Health and Risk Management*, **2009**, 5, 991-1000	4.4	3
58	When is discontinuation of antihypertensive therapy indicated?. *Cardiovascular Drugs and Therapy*, **1990**, 4, 1487-94	3.9	3
57	Dependency of flow-mediated vasodilatation from basal nitric oxide activity. *Clinical Physiology and Functional Imaging*, **2021**, 41, 310-316	2.4	3
56	Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO study. *Journal of Human Hypertension*, **2021**,	2.6	3
55	Lumen narrowing and increased wall to lumen ratio of retinal microcirculation are valuable biomarkers of hypertension-mediated cardiac damage. *Blood Pressure*, **2019**, 1-10	1.7	3
54	How to measure retinal microperfusion in patients with arterial hypertension. *Blood Pressure*, **2021**, 30, 4-19	1.7	3
53	Reference values of retinal microcirculation parameters derived from a population random sample. *Microvascular Research*, **2021**, 134, 104117	3.7	3
52	Long-Term Results up to 12 Months After Catheter-Based Alcohol-Mediated Renal Denervation for Treatment of Resistant Hypertension. *Circulation: Cardiovascular Interventions*, **2021**, 14, e010075	6	3

51	Is l-arginine infusion an adequate tool to assess endothelium-dependent vasodilation of the human renal vasculature?. *Clinical Science*, **2000**, 99, 293-302	6.5	3
50	Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium.. *Circulation*, **2022**, 145, 847-863	16.7	3
49	Retinal Circulation in Arterial Disease **2015**, 397-414		2
48	Current status of renal denervation in resistant hypertension. *Journal of the American Society of Hypertension*, **2012**, 6, 414-6		2
47	Tissue sodium content in hypertension and related organ damage. *Journal of Hypertension*, **2020**, 38, 2363-2368	1.9	2
46	Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers.. *Cardiovascular Diabetology*, **2022**, 21, 4	8.7	2
45	Retinal arterial remodeling in patients with pheochromocytoma or paraganglioma and its reversibility following surgical treatment. *Journal of Hypertension*, **2020**, 38, 1551-1558	1.9	2
44	Two-Year Outcomes of Patients Treated With Aliskiren Under Clinical Practice Conditions: Non-Interventional Prospective Study. *Journal of Clinical Hypertension*, **2016**, 18, 647-54	2.3	2
43	Benefits and Risks of Aliskiren Treatment in Patients With Type 2 Diabetes: Analyses of the 3A Registry. *Journal of Clinical Hypertension*, **2016**, 18, 1045-1053	2.3	2
42	Novel approaches to management of hypertension. *Current Opinion in Nephrology and Hypertension* , **2021**, 30, 54-62	3.5	2
41	Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk. *Journal of Hypertension*, **2021**, 39, 766-774	1.9	2
40	Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure. *ESC Heart Failure*, **2021**,	3.7	2
39	Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine. *Cardiovascular Diabetology*, **2021**, 20, 178	8.7	2
38	Copeptin Levels in Patients With Treatment-Resistant Hypertension Before and 6 Months After Renal Denervation. *American Journal of Hypertension*, **2020**, 33, 182-189	2.3	1
37	1-Year outcomes of hypertension management in 13,000 outpatients under practice conditions: prospective 3A registry. *International Journal of Cardiology*, **2014**, 176, 589-94	3.2	1
36	Hypertonie und Dyslipidämie. *Gastroenterologe*, **2017**, 12, 294-299	0.1	1
35	Managing Treatment-Resistant Patients. *High Blood Pressure and Cardiovascular Prevention*, **2015**, 22 Suppl 1, S11-3	2.9	1
34	Achievement of recommended glucose and blood pressure targets in patients with type 2 diabetes and hypertension in clinical practice - study rationale and protocol of DIALOGUE. *Cardiovascular Diabetology*, **2012**, 11, 148	8.7	1

33	Angiotensin II-type 2 receptor: emerging target for cardiovascular protection. *American Journal of Hypertension*, **2010**, 23, 220	2.3	1
32	Reversal of left ventricular hypertrophy: a desirable therapeutic goal?. *Journal of Cardiovascular Pharmacology*, **1990**, 16 Suppl 6, S16-22	3.1	1
31	The influence of aircraft noise exposure on the systemic and renal haemodynamics. *European Journal of Preventive Cardiology*, **2020**,	3.9	1
30	Neurogenic substance P-influences on action potential production in afferent neurons of the kidney?. *Pflugers Archiv European Journal of Physiology*, **2021**, 473, 633-646	4.6	1
29	Hypertrophic remodelling of retinal arterioles in patients with congestive heart failure. *ESC Heart Failure*, **2021**, 8, 1892-1900	3.7	1
28	Response to: Cavagna et al The importance of considering cultural and environmental elements in an interventional model of care to fight hypertension in Africa. *Journal of Clinical Hypertension*, **2021**, 23, 1271-1272	2.3	1
27	Association of Noise Annoyance with Measured Renal Hemodynamic Changes. *Kidney and Blood Pressure Research*, **2021**, 46, 323-330	3.1	1
26	Renal and intraglomerular haemodynamics in chronic heart failure with preserved and reduced ejection fraction. *ESC Heart Failure*, **2021**, 8, 1562-1570	3.7	1
25	Identifying Isolated Systolic Hypertension From Upper-Arm Cuff Blood Pressure Compared With Invasive Measurements. *Hypertension*, **2021**, 77, 632-639	8.5	1
24	Twenty-Four-Hour Pulsatile Hemodynamics Predict Brachial Blood Pressure Response to Renal Denervation in the SPYRAL HTN-OFF MED Trial.. *Hypertension*, **2022**, 101161HYPERTENSIONAHA12118641	8.5	1
23	Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk.. *Cardiovascular Diabetology*, **2022**, 21, 12	8.7	0
22	Relationship Between Ubiquitin-Specific Peptidase 18 and Hypertension in Polish Adult Male Subjects: A Cross-Sectional Pilot Study. *Medical Science Monitor*, **2020**, 26, e921919	3.2	0
21	Kriterien der Deutschen Gesellschaft f Kardiologie Herz- und Kreislaufforschung e. V. (DGK), der Deutschen Hochdruckliga e. V. DHL /Deutschen Gesellschaft f Hypertonie und Pr vention und der Deutschen Gesellschaft f Nephrologie (DGfN) zur Zertifizierung von Renale-Denervations-Zentren (RDZ) Update. *Kardiologe*, **2021**, 15, 463-470	0.6	0
20	Cardiovascular outcomes in patients at high cardiovascular risk with previous myocardial infarction or stroke. *Journal of Hypertension*, **2021**, 39, 1602-1610	1.9	0
19	Application of a central iliac arteriovenous coupler device in severe treatment-resistant hypertension: a 3.5-year follow-up. *Journal of Hypertension*, **2018**, 36, 2471-2477	1.9	0
18	Tissue sodium content correlates with hypertrophic vascular remodeling in type 2 diabetes. *Journal of Diabetes and Its Complications*, **2021**, 35, 108055	3.2	0
17	Damage of Retinal Arterioles in Hypertension **2015**, 127-142		
16	The impact of age on the benefits and risks of aliskiren treatment: analyses of the 3A registry. *Journal of Human Hypertension*, **2015**, 29, 316-23	2.6	

15	Diabetes und Hypertonie. *Diabetologe*, **2016**, 12, 312-318	0.2
14	Assessment of Target Organ Damage **2018**, 189-199	
13	Increased Aldosterone Release During Head-Up Tilt in Early Primary Hypertension. *American Journal of Hypertension*, **2017**, 30, 484-489	2.3
12	Hypertension and Diabetes: what are the pros to treating early surrogates?. *Diabetes Care*, **2009**, 32 Suppl 2, S294-7	14.6
11	Angiotensin II stimulates left ventricular hypertrophy in hypertensive patients independently of blood pressure. *American Journal of Hypertension*, **1999**, 12, 418-422	2.3
10	Response to: "Response to "Diagnosis and Treatment of Arterial Hypertension 2021".. *Kidney International*, **2022**,	9.9
9	Nephroprotection by antihypertensive agents. *Journal of Cardiovascular Pharmacology*, **1994**, 24 Suppl 2, S55-64	3.1
8	Obese hypertensive patients are less effectively treated than lean hypertensives. *Journal of Hypertension Supplement: Official Journal of the International Society of Hypertension*, **1993**, 11, S348-9	
7	Assessment of Retinal Arteriolar Morphology by SLDF. *Updates in Hypertension and Cardiovascular Protection*, **2020**, 27-41	0.1
6	Alternative Methods for Renal Denervation. *Updates in Hypertension and Cardiovascular Protection*, **2016**, 321-337	0.1
5	The Optic Fundus and Retinal Circulation: New Technology for an Old Examination **2012**, 157-168	
4	Metabolische Wirkungen und kardiovaskuläre Sicherheit einer oralen Dreifachtherapie des Typ-2-Diabetes: das Beispiel Metformin, Empagliflozin und Linagliptin. *Diabetologie Und Stoffwechsel*, **2020**, 15, 317-326	0.7
3	New data, new studies, new hopes for renal denervation in patients with uncontrolled hypertension. *International Journal of Cardiology: Hypertension*, **2019**, 3, 100022	1.6
2	Neurovascular Compression in Arterial Hypertension: Correlation of Clinical Data to 3D-Visualizations of MRI-Findings. *Open Neuroimaging Journal*, **2021**, 14, 16-27	0.1
1	Detection of Changes in Renal Blood Flow Using Arterial Spin Labeling MRI. *American Journal of Nephrology*, **2021**, 52, 69-75	4.6